Abstract:The etiology and pathogenesis of Alzheimer's disease (AD) are not fully understood. Thus, there are no drugs available that can provide a cure for it. We and others found that DNA polymerase-beta (DNA pol-beta) is required for neuronal death in several neurodegenerative models. In the present study, we tested the effect of a DNA pol-beta inhibitor 2',3'-Dideoxycytidine (DDC) in AD models both in vitro and in vivo. DDC protected primary neurons from amyloid-beta (A beta)-induced toxicity by inhibiting aberrant DNA replication mediated by DNA pol-beta. Chronic oral administration of DDC alleviated A beta deposition and memory deficits in the Tg2576 mouse model of AD. Moreover, DDC reversed synaptic loss in Tg2576 mice. These results suggest that DDC represents a novel therapeutic agent for the treatment of AD.

2',3'-Dideoxycytidine, a DNA Polymerase-β Inhibitor, Reverses Memory Deficits in a Mouse Model of Alzheimer's Disease.